Savara to Present at Oppenheimer’s 32nd Annual Healthcare Conference

Rhea-AI Summary

Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company, announced its participation in Oppenheimer’s 32nd Annual Healthcare Conference on March 16, 2022, at 3:20 pm ET. The presentation will focus on their lead program, molgramostim, an inhaled treatment for autoimmune pulmonary alveolar proteinosis (aPAP), currently in Phase 3 development. A live webcast will be available on Savara’s website and archived for 90 days. Savara is dedicated to advancing therapies for rare respiratory diseases.

AUSTIN, Texas--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at Oppenheimer’s 32nd Annual Healthcare Conference on March 16, 2022 at 3:20 pm ET. A live webcast of the presentation will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220309005067/en/

Savara Inc. IR & PR

Anne Erickson

Senior Vice President, Chief of Staff

anne.erickson@savarapharma.com

(512) 851-1366

Source: Savara Inc.

FAQ

When will Savara Inc. present at the Oppenheimer Healthcare Conference?

Savara Inc. will present on March 16, 2022, at 3:20 pm ET.

What is the focus of Savara Inc.'s presentation at the conference?

The presentation will focus on molgramostim, an inhaled treatment for autoimmune pulmonary alveolar proteinosis (aPAP).

Where can I watch Savara Inc.'s presentation at the Oppenheimer Conference?

The presentation will be available as a live webcast on Savara's website, archived for 90 days.

What is molgramostim and its significance for Savara Inc.?

Molgramostim is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for treating aPAP.

What is the stock symbol for Savara Inc.?

The stock symbol for Savara Inc. is SVRA.